Hypericum for depression: An update of the clinical evidence
- 31 December 1999
- journal article
- editorial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9 (6) , 501-505
- https://doi.org/10.1016/s0924-977x(99)00032-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- St. John's Wort in Mild to Moderate Depression: The Relevance of Hyperforin for the Clinical EfficacyPharmacopsychiatry, 1998
- Activity Profiles of Two Hyperforin-Containing Hypericum Extracts in Behavioral ModelsPharmacopsychiatry, 1998
- Hyperforin Represents the Neurotransmitter Reuptake Inhibiting Constituent of Hypericum ExtractPharmacopsychiatry, 1998
- Efficacy and Tolerability of St. John's Wort Extract LI 160 Versus Imipramine in Patients with Severe Depressive Episodes According to ICD-10Pharmacopsychiatry, 1997
- LI 160, an Extract of St. John's Wort, Versus Amitriptyline in Mildly to Moderately Depressed Outpatients - A Controlled 6-Week Clinical TrialPharmacopsychiatry, 1997
- Effects of Hypericum Extract (LI 160) in Biochemical Models of Antidepressant ActivityPharmacopsychiatry, 1997
- St John's wort as an antidepressantBMJ, 1996
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- A New Italian Pedigree with Early-Onset Alzheimer's DiseaseJournal of Geriatric Psychiatry and Neurology, 1994
- Recognition and management of depression in general practice: consensus statement.BMJ, 1992